<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70675">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02139241</url>
  </required_header>
  <id_info>
    <org_study_id>Ramosetron_opcab</org_study_id>
    <nct_id>NCT02139241</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery</brief_title>
  <official_title>The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of ramosetron on corrected QT interval in
      patients undergoing off pump coronary artery bypass surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>corrected QT interval (QTc interval)</measure>
    <time_frame>up to 240 minutes after induction of general anesthesia</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>at 1,2,3,5,10,15,30,45,60,90,120,240 minutes after ramosetron injection, at the time of operation end, ICU 12hour</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hypotension or bradycardia during the peri-induction period and the coronary anastomosis period</measure>
    <time_frame>up to 240 minutes after induction of general anesthesia</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of postoperative atrial fibrillation</measure>
    <time_frame>during the hospital stay (from ICU admission to hospital discharge, average of 1 week)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Coronary Artery Bypass Graft Triple Vessel</condition>
  <condition>Hypotension</condition>
  <arm_group>
    <arm_group_label>Ramosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous administration of ramosetron 0.3 mg before the induction of general anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous administration of 2ml normal saline before the induction of general anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron</intervention_name>
    <description>0.3 mg IV as bolus before induction of general anesthesia</description>
    <arm_group_label>Ramosetron</arm_group_label>
    <other_name>Nasea</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>2 ml normal saline as bolus before induction of general anesthesia</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective off-pump coronary artery bypass graft surgery

        Exclusion Criteria:

          -  Emergency operation

          -  preoperative use of any inotropics or mechanical assist device

          -  severe liver disease (&gt;Child class II)

          -  dialysis dependent renal failure

          -  Left ventricular ejection fraction &lt;30 %

          -  Combined major surgery like carotid endarterectomy

          -  Previous allergy history to any 5-hydroxytryptamine type 3 (5-HT3) antagonist

          -  Preoperative QT prolongation ( 500 &gt;msec) or arrhythmia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yunseok Jeon, PhD</last_name>
    <phone>82-2-2072-2467</phone>
    <email>jeonyunseok@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunseok Jeon, PhD</last_name>
      <phone>82-2-2072-2467</phone>
      <email>jeonyunseok@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Havrilla PL, Kane-Gill SL, Verrico MM, Seybert AL, Reis SE. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother. 2009 Mar;43(3):532-6. doi: 10.1345/aph.1L544. Epub 2009 Mar 3.</citation>
    <PMID>19261954</PMID>
  </reference>
  <reference>
    <citation>Sahoo T, SenDasgupta C, Goswami A, Hazra A. Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study. Int J Obstet Anesth. 2012 Jan;21(1):24-8. doi: 10.1016/j.ijoa.2011.08.002. Epub 2011 Nov 18.</citation>
    <PMID>22100822</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
